Heron Therapeutics (HRTX) Accounts Payables (2010 - 2026)

Heron Therapeutics has reported Accounts Payables for 17 years, with the latest figure at $9.0 million in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables fell 27.27% year-over-year to $9.0 million; the trailing twelve-month figure through Mar 2026 stood at $9.0 million (down 27.27% YoY), and the FY2025 full-year result was $9.0 million, down 23.19% from the prior year.
• Accounts Payables for Q1 2026 stood at $9.0 million, roughly flat from $9.0 million in the prior quarter.
• The five-year high for Accounts Payables was $13.8 million in Q2 2022, with the low at $559000.0 in Q4 2023.
• Historically, Accounts Payables has averaged $7.5 million across 5 years, with a median of $9.0 million in 2026.
• Annual changes were most pronounced in 2022 — Accounts Payables jumped 4507.14% — and 2023, when it sank 85.82%.
• Heron Therapeutics' Accounts Payables stood at $3.2 million in 2022, then plunged by 82.67% to $559000.0 in 2023, then soared by 1994.63% to $11.7 million in 2024, then declined by 23.19% to $9.0 million in 2025, then dropped by 0.27% to $9.0 million in 2026.
• The last three Accounts Payables figures came in at $9.0 million (Q1 2026), $9.0 million (Q4 2025), and $12.0 million (Q3 2025), per Business Quant data.